Table 1.

Basic characteristics of analyzed studies with bevacizumab and irinotecan

Study	Number of patients	Sex (n)		Median age, years (range)	Histology (n)		Treatment
		Male	Female		WHO IV	WHO III
Bokstein et al47	20	14	6	56 (38–74)	17	3	Bevacizumab (5 mg/kg) + irinotecan (125 mg/m2) every 14 days
Desjardins et al42	33	22	11	43 (22–62)	0	33	Bevacizumab (10 mg/kg) + irinotecan (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 14 days, bevacizumab (15 mg/kg) Q21d + irinotecan (340 mg/m2 for EIAED, 125 mg/m2 for non-EIAED) on days 1, 8, 22, and 29, on a 6-week cycle
Friedman et al43	82	57	25	57 (23–79)	82	0	Bevacizumab (10 mg/kg) + irinotecan (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 weeks
Kreisl et al44	48	28	20	53 (21–69)	48	0	Bevacizumab (10 mg/kg) + irinotecan (340 mg/m2 for EIAED or 125 mg/m2 for non-EIAED) every 2 weeks
Poulsen et al48	52	34	18	46 (26–67)	28	24	Bevacizumab (10 mg/kg) + irinotecan (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 weeks
Vredenburg et al45	35	22	13	48 (18–66)	35	0	Bevacizumab (10 mg/kg) + irinotecan (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 14 days, bevacizumab (15 mg/kg) Q21d + irinotecan (340 mg/m2 for EIAED, 125 mg/m2 for non-EIAED) on days 1, 8, 22, and 29, on a 6-week cycle
Vredenburg et al38	32	21	11	49 (27–66)	23	9	Bevacizumab (10 mg/kg) + irinotecan (340 mg/m2 for EIAED or 125 mg/m2 for non-EIAED) every 2 weeks

Abbreviations: EIAED, enzyme-inducing antiepileptic drugs; Q21d, every 21 days; WHO, World Health Organization.